NCT01469078已完成1 期
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D) (PK-CKD-05)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 主要终点
- Determination of changes in Iron pharmacokinetic parameters from plasma/serum concentration profile
研究概览
简要总结
The purpose of this study is to assess Pharmakokinetic properties of iron isomaltoside 1000 (Monofer®) in doses of 100 mg, 200 mg or 500 mg in subjects with Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women, aged more than 18 years.
- •Weight above 50 kg.
- •Subjects diagnosed with CKD-5D and on dialysis therapy for at least 90 days prior to inclusion.
- •Serum ferritin ≤ 800 ng/mL.
- •Transferrin Saturation ≤ 35%.
- •Life expectancy beyond 12 months by Principal Investigator's judgement.
- •Hb concentrations ≥10.0 g/dL and ≤12.5 g/dL both at Screening Visit 1a and at Screening Visit 1b (Screening Visit 1a and Visit 1b must be separated by at least 1 week).
- •Erythropoiesis Stimulating Agent (ESA) treatment (to be kept constant during the study period and for 4 weeks prior to inclusion with only one missed dose to be allowed during this pre-entry period).
- •Subjects in maintenance iron therapy with average iron administration ≤ 100 mg/week for 4 weeks prior to inclusion and willingness to switch to investigational product.
- •Willingness and ability to participate after informed consent (including HIPAA, if applicable).
排除标准
- •Anemia caused primarily by other factors than renal related anemia.
- •Iron overload or disturbances in utilization of iron (e.g. hemochromatosis and hemosiderosis).
- •Difference of Hb ≥ 1.0 g/dL between Screening Visits 1a and 1b.
- •Known hypersensitivity to any excipients in the investigational drug products.
- •Subjects with a history of multiple allergies.
- •Decompensated liver cirrhosis and history of hepatitis B or C [Alanine Aminotransferase (ALT) > 3 times upper limit of normal].
- •Acute or chronic infections (assessed by clinical investigator judgment), supported by White Blood Cells (WBC) and C-Reactive Protein (CRP).
- •Rheumatoid arthritis with symptoms or signs of active joint inflammation.
- •Pregnant or nursing women.
- •Women of child bearing potential who are not using safe contraceptive methods (e.g. intrauterine device, oral contraceptives or surgically sterilized) or who are planning to become pregnant within the study period.
- •Blood transfusion within the previous 12 weeks.
- •Planned elective surgery during the study where significant blood loss is expected.
- •Participation in any other clinical trial within 3 months prior to screening.
- •Untreated Vitamin B12 or folate deficiency.
- •Any other medical condition that, in the opinion of Principal Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study. Examples include Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus.
研究组 & 干预措施
100 mg Monofer®
Active Comparator
干预措施: Monofer® (Drug)
200 mg Monofer®
Active Comparator
干预措施: Monofer® (Drug)
500 mg Monofer®
Active Comparator
干预措施: Monofer® (Drug)
结局指标
主要结局
Determination of changes in Iron pharmacokinetic parameters from plasma/serum concentration profile
时间窗: From exposure to 7 days post-exposure
The follwoing parameter will be determined: AUC0-t, AUC, Cmax, Tmax, Ke, and T1/2
次要结局
- Changes in pharmacodynamic parametres(From 0 hours to 4, 8, 24, 48, 72 hours post-exposure and end of study visit)
- Safety evaluation(From screening to 7 days post-exposure)
研究者
相似试验
已完成
1 期
Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced AnaemiaPatients With Chemotherapy Induced Anemia (CIA)NCT01280240Pharmacosmos A/S11
已完成
1 期
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)Non-hematological MalignanciesNCT01213979Pharmacosmos A/S16
已完成
1 期
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous to Patients With CKDNon-dialysis Dependent Chronic Kidney DiseaseNCT01213992Pharmacosmos A/S16
已完成
1 期
Open-label PK Study of Iron Isomaltoside 1000 (Monofer) Administered by 500 mg IV Injection or 1000 mg IV Infusion to Patients With Inflammatory Bowel DiseaseInflammatory Bowel DiseaseNCT01213680Pharmacosmos A/S16
已完成
3 期
IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron SucroseIron Deficiency AnaemiaNCT02130063Pharmacosmos A/S511